Omeros logo

Omeros

OMER | NASDAQ
Chart Builder DCF Calculator
$16.68
-$0.81 (-4.63%)
At close: Nov 16, 2026, 4:00 PM ET
$15.40
-$1.28 (-7.67%)
After-hours: Nov 16, 2026, 7:59 PM ET
-4.63%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
70.3
-1.5 pts
Fundamentals Excellent
Market Sentiment Neutral
Moat None
Sector Rank #55/1021 (Top 5%)

Key Statistics

Market Data

Market Cap $1.21B
1D Range
16.65 17.48
52W Range
8.22 21.05

Valuation (TTM)

PE 9.70
PB -23.51
EV/EBITDA 8.72

Valuation (NTM)

Forward PE 21.33
Forward PEG -0.07
Price Target $27.50
Loading financial charts...

Profile

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies,...

Sector Healthcare
Industry Biotechnology
Employees 175
IPO Date Oct 8, 2009
Fiscal Year January - December

Latest News

Omeros Q3 Earnings Call Highlights

5 hours ago · marketbeat.com

Omeros Q3 Earnings Call Highlights
Omeros Corporation (OMER) Q3 2026 Earnings Call Transcript

5 hours ago · seekingalpha.com

Omeros Corporation (OMER) Q3 2026 Earnings Call Transcript
Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates

7 hours ago · zacks.com

Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates
Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026

6 days ago · businesswire.com

Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

1 month ago · benzinga.com

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

1 month ago · businesswire.com

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

2 months ago · benzinga.com

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

3 months ago · zacks.com

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

3 months ago · zacks.com

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?
Omeros Q1 Earnings Call Highlights

6 months ago · marketbeat.com

Omeros Q1 Earnings Call Highlights

Earnings

Latest Earnings
Nov 16, 2026
EPS
$0.06
Beat +200.00%
REV
$35.93M
Miss -3.61%
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$27.50
Upside
+64.87%
Buy (3)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.